Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 2

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Pancreatic Neoplasms 2

Interventions

Oxaliplatin 1004Fluorouracil 800Capecitabine 764Gemcitabine 650Leucovorin 559Irinotecan 537Bevacizumab 513Radiotherapy 460Cisplatin 440Drug Therapy 298Cetuximab 280Surgical Procedures, Operative 229Paclitaxel 228S 1 (combination) 217pembrolizumab 205Docetaxel 199130-nm albumin-bound paclitaxel 196Nivolumab 193sintilimab 191Radiosurgery 190lenvatinib 180Folfox protocol 179Sorafenib 178Albumin-Bound Paclitaxel 173apatinib 170tislelizumab 161camrelizumab 160Neoadjuvant Therapy 158Blood Specimen Collection 154durvalumab 148

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × NIS-793 × Gastrointestinal × Clear all
NCT05417386 2025-11-18

FOLFIRINOX + NIS793 in Pancreatic Cancer

Massachusetts General Hospital

Phase 1 Terminated
4 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT05546411 2024-12-17

A Trial of NIS793 With FOLFIRINOX in Pancreatic Cancer

Dana-Farber Cancer Institute

Phase 2 Terminated
8 enrolled 11 charts
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡